Security key
69353Y103
PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (PMVP)
CUSIP: 69353Y103
Q2 2023 13F Holders as of 30 Jun 2023
- Security type / class
- Equity / Common Stock, $0.00001 par value per share
- Total 13F shares
- 51,696,984
- Total 13F value
- $323,689,509
- Share change
- +246,162
- Put/Call ratio
- 17%
- SEC-reported price per share
- $6.26
- Number of holders
- 104
- Value change
- +$3,281,155
- Number of buys
- 58
- Number of sells
- 53
- Shares outstanding
- 53,625,367
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2023
Institutions
104
Top holders
10
PMVP full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2023
Previous quarter: Q1 2023
PMV Pharmaceuticals, Inc. SEC filings
PMV Pharmaceuticals, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 69353Y103
Recent filing periods:
Ownership snapshot
Top reported holders of PMVP - PMV Pharmaceuticals, Inc. - Common Stock, $0.00001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2023
13F
3/4/5
Lead comparable stake: 12%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 12%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
12%
BlackRock Finance, Inc.
7.5%
JPMORGAN CHASE & CO
7.5%
Boxer Capital, LLC
5.9%
Avoro Capital Advisors LLC
5.7%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
12%
|
$31,305,877
6,563,077 shares
|
— | 31 Mar 2023 |
| BlackRock Finance, Inc. |
13F
Company
|
7.5%
|
$19,223,905
4,030,169 shares
|
— | 31 Mar 2023 |
| JPMORGAN CHASE & CO |
13F
Company
|
7.5%
|
$19,094,000
4,002,874 shares
|
— | 31 Mar 2023 |
| Boxer Capital, LLC |
13F
Company
|
5.9%
|
$15,091,000
3,163,795 shares
|
— | 31 Mar 2023 |
| Avoro Capital Advisors LLC |
13F
Company
|
5.7%
|
$14,596,200
3,060,000 shares
|
— | 31 Mar 2023 |
| RTW INVESTMENTS, LP |
13F
Company
|
5.6%
|
$14,305,697
2,999,098 shares
|
— | 31 Mar 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
104
Shares
51,696,984
Rows available
104
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2023 vs Q1 2023 Across Filers
Q1 2023 holders
111
Q2 2023 holders
104
Holder diff
-7
| Investor | Q1 2023 Shares | Q2 2023 Shares | Share Diff | Share Chg % | Q1 2023 value | Q2 2023 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend